



**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

June 15, 1987

#28

Leonard P. Prusak  
Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003

RE: Patent Term Extension  
Application for  
U.S. Patent No. 4,361,549  
Issued November 30, 1984

**NOTICE OF FINAL DETERMINATION**

A determination has been made that U.S. Patent No. 4,361,549, issued November 30, 1982, is eligible for patent term extension under 35 USC 156. The period of extension has been determined to be 201 days.

The period of extension has been calculated using the FDA determination of the length of the regulatory review period published in the Federal Register on November 20, 1986, as follows:

$$\begin{aligned}\text{Period} &= \frac{1}{2} (\text{Testing Phase}) + \text{Approval Phase} \\ &= \frac{1}{2} (1488) + 813 \\ &= 1557 \text{ days}\end{aligned}$$

Since the regulatory review period began (March 13, 1980) before the patent issued (November 30, 1982), only that portion of the regulatory review period occurring after the date the patent issued has been considered in the determination of the length of the maximum extension. 35 USC 156(c). (From March 3, 1980 to November 30, 1982 is 1002 days, this period is subtracted from the number of days occurring in the testing phase according to the FDA determination of the length of the regulatory period:  $1488 - 1002 = 486$  days.) No determination of a lack of due diligence was made. 35 USC 156(c)(1). The exception of 35 USC 156(c)(3) operates to limit the term of extension in the present situation because it provides that the period remaining in the term of the patent measured from the date of approval of the approved product (June 19, 1986) when added to the period of extension calculated above (1557) cannot exceed 14 years. The period of extension is thus limited to June 19, 2000, by operation of 35 USC 156(c)(3). Since the patent term of seventeen (17) year (35 USC 154) would expire on November 30, 1999, the period of extension is the number of days to extend the term of the patent to June 19, 2000, or 201 days. The limitations of 35 USC 156(g)(4) do not operate to reduce the period of extension determined above.

166

A single request for reconsideration of this final determination as to eligibility and the length of extension of the term of U.S. Patent 4,361,549 may be made if filed within one (1) month of the date of this notice. In the absence of such request, the Commissioner will issue to the applicant for extension of the term of Patent No. 4,361,549, a certificate of extension, under seal, for a period of 201 days. The rights derived from the patent during the period during which the patent is extended are defined in 35 USC 156(b).

C. E. Van Horn

Charles E. Van Horn, Director  
Patent Examining Group 120

cc: Ronald L. Wilson, Director  
Health Assessment Policy Staff  
Office of Health Affairs  
Food & Drug Administration  
5600 Fishers Lane  
Rockville, MD 20857

RE: ORTHOCLONE OKT\*3  
FDA Docket # 86E-0357

167